Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Corneal Thinning During Topical Bevacizumab Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00515684
Recruitment Status : Withdrawn (Side effect can increase the risk of the research)
First Posted : August 14, 2007
Last Update Posted : May 1, 2015
Sponsor:
Information provided by:
Yonsei University

Brief Summary:
The purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period.

Condition or disease Intervention/treatment Phase
Corneal Neovascularization Drug: bevacizumab (Avastin) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Study Start Date : May 2007
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • clinical diagnosis of corneal neovascularization
  • must be able to apply eyedrop

Exclusion Criteria:

  • have active keratitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00515684


Locations
Layout table for location information
Korea, Republic of
Severance hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Yonsei University
Investigators
Layout table for investigator information
Principal Investigator: Sang Woo Kim, M.D. Severance hospital, Seoul , Korea

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00515684    
Other Study ID Numbers: 4-2006-0234
First Posted: August 14, 2007    Key Record Dates
Last Update Posted: May 1, 2015
Last Verified: April 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Corneal Neovascularization
Neovascularization, Pathologic
Metaplasia
Pathologic Processes
Corneal Diseases
Eye Diseases
Bevacizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors